How did Zoetis' revenue perform in the second quarter of 2020?

Zoetis reported total revenue of $1,548 million for the three months ended June 30, 2020, which was flat compared to the $1,547 million reported in the same period of 2019. However, on an operational basis, excluding the impact of foreign exchange, revenue increased by 4%.

What was the impact of COVID-19 on Zoetis' business during this period?

The COVID-19 pandemic had a significant impact, particularly on the livestock segment, due to disruptions in the food supply chain, reduced producer processing capacity, and decreased demand for veterinary services in the companion animal segment. The company was designated an essential business and continued operations, but anticipates these impacts to continue for the remainder of 2020. Selling, general, and administrative expenses decreased due to lower travel and entertainment expenses related to the pandemic.

How did Zoetis manage its debt and liquidity?

Zoetis' cash and cash equivalents significantly increased to $3,353 million as of June 30, 2020. In May 2020, the company issued $1.25 billion in senior notes, using the proceeds to repay $500 million of maturing debt and for general corporate purposes, thereby strengthening its liquidity position. The company remained in compliance with its debt covenants.

What were the key drivers of revenue growth in the companion animal segment?

Growth in companion animal products was primarily driven by increased sales in the Simparica franchise, including the launch of Simparica Trio, as well as growth in its key dermatology portfolio and contributions from recent acquisitions of diagnostic reference labs.

ZTS 10-Q Quarterly Report Q2 FY2020 — Revenue, Net Income, EPS

Summary

Zoetis Inc. reported flat revenue of $1,548 million for the three months ended June 30, 2020, compared to the same period in 2019. On an operational basis, excluding foreign exchange impacts, revenue grew by 4%. Net income attributable to Zoetis Inc. increased by 2% to $377 million for the quarter. For the six months ended June 30, 2020, revenue increased by 3% to $3,082 million (5% operationally), and net income attributable to Zoetis Inc. grew by 17% to $800 million. The company highlighted strong performance in companion animal products, particularly the Simparica franchise, which offset declines in certain livestock segments impacted by COVID-19 related supply chain disruptions. Despite the slight revenue dip in reported terms for the quarter, the company demonstrated resilience. Cash and cash equivalents saw a significant increase to $3,353 million from $1,934 million at the end of 2019, primarily due to strong operating cash flows and proceeds from debt issuance. Zoetis also managed its expenses effectively, with selling, general, and administrative expenses decreasing due to lower travel and entertainment costs related to the pandemic. The company continues to invest in research and development, with R&D expenses remaining stable year-over-year for the quarter and increasing slightly for the six-month period.

Financial Highlights

52 data points

Beta

Revenue

$1.55B

0.7% Gross Margin

Net Income

$376.00M

0.2% Net Margin

EPS (Diluted)

$0.79

Total Assets

$13.07B

Cash & Equivalents

$3.35B

Free Cash Flow

$348.00M

Financial Statements

Beta

Revenue	$1.55B
Cost of Revenue	$451.00M
Gross Profit	$1.10B
SG&A Expenses	$393.00M
Interest Expense	$58.00M
Net Income	$376.00M
EPS (Basic)	$0.79
EPS (Diluted)	$0.79
Shares Outstanding (Basic)	475.30M
Shares Outstanding (Diluted)	478.10M

Key Highlights

1Revenue remained flat at $1,548 million for the three months ended June 30, 2020, but showed 4% operational growth excluding foreign exchange effects.
2Net income attributable to Zoetis Inc. increased by 2% to $377 million for the three months ended June 30, 2020.
3For the six months ended June 30, 2020, revenue grew 3% to $3,082 million (5% operationally) and net income increased 17% to $800 million.
4Companion animal products, particularly the Simparica franchise, showed strong performance, with an 11% increase in revenue for the quarter and 10% for the six-month period.
5Livestock product revenue declined by 10% for the quarter and 5% for the six-month period, impacted by COVID-19 related supply chain disruptions and unfavorable market conditions.
6Cash and cash equivalents significantly increased to $3,353 million as of June 30, 2020, up from $1,934 million at December 31, 2019.
7The company issued $1.25 billion in senior notes in May 2020, strengthening its liquidity position.

Zoetis Inc. Quarterly Report for Q2 Ended Jun 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions